Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ALK-Abelló A/S
  6. Summary
    ALK B   DK0060027142

ALK-ABELLÓ A/S

(ALK B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
2748(c) 2766(c) 2870(c) 2914(c) 2892(c) Last
3 303 4 333 11 934 12 647 6 244 Volume
-0.07% +0.66% +3.76% +1.53% -0.75% Change
More quotes
Financials
Sales 2021 3 871 M 630 M 630 M
Net income 2021 111 M 18,0 M 18,0 M
Net Debt 2021 785 M 128 M 128 M
P/E ratio 2021 291x
Yield 2021 0,06%
Sales 2022 4 350 M 708 M 708 M
Net income 2022 379 M 61,7 M 61,7 M
Net Debt 2022 541 M 88,1 M 88,1 M
P/E ratio 2022 84,9x
Yield 2022 0,09%
Capitalization 31 745 M 5 166 M 5 169 M
EV / Sales 2021 8,40x
EV / Sales 2022 7,42x
Nbr of Employees 2 459
Free-Float 89,4%
More Financials
Company
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines... 
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of ALK-Abelló A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALK-ABELLÓ A/S
05/10ALK ABELLÓ A/S  : Report on transactions with ALK-Abelló A/S B-shares and associ..
AQ
05/05Three-month interim report (Q1) 2021
GL
04/28ALK ABELLÓ A/S  : Release date of three-month interim report (Q1) 2021 for ALK a..
AQ
04/19ALK ABELLÓ A/S  : gains paediatric approval for its ragweed SLIT-tablet in the U..
AQ
03/26ALK ABELLÓ A/S  : Grant of share options and performance shares to members of th..
AQ
03/18ALK ABELLÓ A/S  : Annual General Meeting in ALK-Abelló A/S held on 18 March 2021
AQ
03/02ALK ABELLÓ A/S  : Report on transactions with ALK-Abelló A/S B-shares and associ..
AQ
03/01195;rsted A/S Resolutions Of The Annual General Meeting 2021 Of Ørsted A/S
DJ
02/24ALK ABELLÓ A/S  : Report on transactions with ALK-Abelló A/S B-shares and associ..
PU
02/23ALK ABELLÓ A/S  : Annual General Meeting in ALK-Abelló A/S on 18 March 2021
AQ
02/19ALK ABELLÓ A/S  : Report on transactions with ALK-Abelló A/S B-shares and associ..
AQ
02/10ALK ABELLÓ A/S  : Abelló Turns To Profit in FY20; Shares Up 4%
MT
02/10ALK releases 2020 annual report
GL
02/04ALK ABELLÓ A/S  : Release date of annual report 2020 for ALK and audio cast
AQ
2020ALK ABELLÓ A/S  : – Financial calendar for the 2021 financial year
AQ
More news
News in other languages on ALK-ABELLÓ A/S
03/24Brillenhersteller Rodenstock wechselt Eigentümer
03/24Brillenkonzern Rodenstock für 1,5 Milliarden Euro verkauft
01/08Donald Trump s'efface (pour le moment)
01/08AVIS D'ANALYSTES DU JOUR  : AB Inbev, BE Semi, Danone, Elis, Gecina, Idorsia, Ip..
2020AVIS D'ANALYSTES DU JOUR  : ASOS, Avast, BMW, Crédit Agricole, Idorsia, Natixis,..
More news
Stock Trading Strategies
ALK-ABELLÓ A/S - 2020
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ALK-ABELLÓ A/S
Duration : Period :
ALK-Abelló A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALK-ABELLÓ A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 3 062,50 DKK
Last Close Price 2 892,00 DKK
Spread / Highest target 22,8%
Spread / Average Target 5,90%
Spread / Lowest Target -13,6%
EPS Revisions
Managers and Directors
NameTitle
Carsten Hellmann President & Chief Executive Officer
Søren Jelert Chief Financial Officer & Executive Vice President
Anders Hedegaard Chairman
Henrik Hugo Jacobi Executive Vice President-Research & Development
Gonzalo de Miquel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALK-ABELLÓ A/S15.68%5 166
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857